MedPage Today
A head-to-head comparison in Great Britain between bevacizumab (Avastin) and ranibizumab (Lucentis) for wet age-related macular degeneration (AMD) adds to mounting evidence that both agents are equals in improving visual acuity.
Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.
OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.
Learn more about writing for us